Chemotherapy,transarterial chemoembolization,and nephrectomy combined treated one giant renal cell carcinoma(T3aN1M1)associated with Xp11.2/TFE3:A case report

作     者：Peng Wang Xiao Zhang Shuo-Han Shao Fa Wu Fei-Zhou Du Jun-Feng Zhang Zhi-Way Zuo Rui Jiang 

作者机构：Department of RadiologyThe General Hospital of Western Theater CommandChengdu 610083Sichuan ProvinceChina 

出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)

年 卷 期：2022年第10卷第28期

页      面：10180-10185页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Supported by the Research and Development Program of The General Hospital of Western Theater Command No.2021-XZYG-C04 and 2021-XZYG-C05 

主　　题：Xp11.2/TFE3 Renal Cell Carcinoma TACE Axitinib Zoledronic Acid Targeted therapy Multimodal imaging Case report 

摘      要：BACKGROUND Renal cell carcinoma(RCC)with Xp11.2 translocation/TFE3 gene fusion is a rare and distinct subtype of RCC that is classified under tumors with translocation of the microphthalmia-associated transcriptional *** SUMMARY We report an adult case of Xp11.2 translocation advanced RCC with metastasis(T3a N1M1),after targeted treatment,alcohol ablation,and transarterial chemoembolization,who eventually underwent successful surgical *** recurrence or transfer was seen within one year,and the survival period was more than 3 years.A review of the relevant literature was conducted to improve our understanding of the pathogenesis,epidemiology,clinical manifestations,diagnosis,differential diagnosis,treatment,and other aspects of the *** Transarterial chemoembolization and ablation did not achieve the desired tumor reduction in this patient,but had a significant effect on reducing intraoperative bleeding and inhibiting tumor activity.